Medicinova opened lower at $1.40, compared with its previous close of $1.41. In the last trading session, the stock traded between $1.40 and $1.42. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Medicinova is now worth
$ 40.11
Resulting in a loss of
$ 59.89 (59.89%)
Invest with $1
Note: Past profits do not guarantee future returns.
Phase 2 trial of MN-001 in NAFLD and T2DM failed to meet primary statistical endpoints. Statistically significant improvements seen in HDL-C and HDL particle concentration. No drug-related serious adverse events reported across the 24-week study period. Topline results for MN-166 ALS trial expected by year-end following last patient visit.
1mo ago
28Sep
MediciNova shares fall 26% as Phase 2 drug misses liver fat target
MediciNova shares fell 26.36% to $2.36 on Monday following mixed Phase 2 trial results. Serum triglyceride reduction lost statistical significance by Week 24 (p=0.113). HDL cholesterol and particle concentration showed significant improvements at Week 24. Liver fat reduction trended positively but did not reach statistical significance (p=0.2438).
1mo ago
24Sep
MediciNova completes double-blind phase of COMBAT-ALS trial
MediciNova completed the double-blind portion of its Phase 2b/3 COMBAT-ALS trial for MN-166. Topline results from the double-blind phase are expected by the end of 2026. Full study LPLV, including open-label extension, is scheduled for March 2027. Trial randomized 234 participants across two treatment arms in the US and Canada.
1mo ago
17Sep
Roth Capital initiates MediciNova coverage with Buy rating, $6 target
Roth Capital initiates coverage on MediciNova (NASDAQ: MNOV). Analyst Boobalan Pachaiyappan assigns a Buy rating. Price target set at $6 per share.
